NL-OMON43714CompletedPhase 2
A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - PRM-151-202
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Promedior, Inc
- Enrollment
- 21
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1. Subject is aged 40-80 years.
- •2. Subject has IPF satisfying the ATS/ERS/JRS/ALAT diagnostic criteria (Raghu, Collard et al. 2011).
- •In the absence of a surgical lung biopsy, HRCT must be *consistent with UIP* defined as meeting either criteria A, B, and C, or criteria A and C, or criteria B and C below:
- •A. Definite honeycomb lung destruction with basal and peripheral predominance.
- •B. Presence of reticular abnormality AND traction bronchiectasis consistent with fibrosis, with basal and peripheral predominance.
- •C. Atypical features are absent, specifically nodules and consolidation. Ground glass opacity, if present, is less extensive than reticular opacity pattern.
- •3. If on pirfenidone or nintedanib, subject must have been on a stable dose of pirfenidone or nintedanib for at least 3 months prior to screening without increase in FVC% predicted on two consecutive PFTs, including screening PFTs. Subjects may not be on both pirfenidone and nintedanib.
- •4. If not currently receiving pirfenidone or nintedanib, subject must have been off pirfenidone or nintedanib for * 4 weeks before baseline.
- •5. Subject has a FVC * 50% and * 90% of predicted.
- •6. Subject has a DLCO * 25% and * 90% of predicted.
- •7. Minimum distance on 6MWT of 150 meters, with or without supplemental oxygen
- •8. Subject has a forced expiratory volume in 1 second (FEV1)/FVC ratio > 0.70.
- •9. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if * 55 years or 12 months if > 55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence (only if total abstinence is the preferred method and usual lifestyle of the subject).
- •10. Subject has a life expectancy of at least 9 months
- •11. Subject, according to the investigator*s best judgment, can comply with the requirements of the protocol.
- •12. Subject and the treating physician considered all medicinal treatment options and/or possibly a lung transplantation prior to considering participation in the study. If the subject is on a lung transplant list, the Investigator anticipates the subject will be able to complete the study prior to transplant.
- •13. Subject has provided written informed consent to participate in the study.
Exclusion Criteria
- •1. Subject has emphysema * 50% on HRCT or the extent of emphysema is greater than the extent of fibrosis according to the reported results of the most recent HRCT.
- •2. Subject has a history of cigarette smoking within the previous 3 months.
- •3. Subject has received investigational therapy for IPF within 4 weeks before baseline.
- •4. Subject is receiving systemic corticosteroids equivalent to prednisone > 10 mg/day or equivalent within 2 weeks of baseline.
- •5. Subjects received Immuno-suppressants (e.g. methotrexate, azathioprine, cyclophosphamide, cyclosporine, everolimus or other immunosuppressants including those used after organ transplant) are prohibited within 4 weeks of baseline and during the study.
- •6. Subject has a history of a malignancy within the previous 5 years, with the exception of basal cell skin neoplasms. In addition, a malignant diagnosis or condition first occurring prior to 5 years must be considered cured, inactive, and not under current treatment.
- •7. Subject has any concurrent condition other than IPF that, in the Investigator*s opinion, is unstable and/or would impact the likelihood of survival for the study duration or the subject*s ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study.
- •8. Subject has baseline resting oxygen saturation of < 89% on room air or with supplemental oxygen.
- •9. Subjects that are unable to refrain from use of the following:
- •a. Short acting bronchodilators on the day of and within 12 hours of pulmonary function, DLco, and 6 minute walk assessments.
- •b. Long acting bronchodilators on the day of and within 24 hours of these assessments.
- •10. Subject has a known post bronchodilator (short acting beta agonist [SABA] * albuterol or salbutamol) increase in FEV1 of >10% and in FVC of >7.5%.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A study to test intravenous PRM-151 for safety and to see how PRM-151 acts in the body and blood of people with idiopathic pulmonary fibrosis (IPF) - a disorder where lung tissue becomes damaged and scarred making it difficult to breathe.EUCTR2014-004782-24-NLPromedior inc60
Unknown
Phase 2
Phase 2 Study of MR13A9.JPRN-jRCT2080223210Maruishi Pharmaceutical Co., Ltd.100
Completed
Not Applicable
Phase II study evaluating safety and efficacy of maintenance therapy with bortezomib, lenalidomide and dexamethasone for multiple myelomaMultiple MyelomaJPRN-UMIN000008236Fourth Department of Internal Medicine, Sapporo Medical University Hospital30
Completed
Phase 2
Phase II trial evaluating safety and efficacy of ME2136 combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapySolid cancerJPRN-jRCT2041200071Yasui Hirofumi40
Completed
Not Applicable
Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myelomaMultiple MyelomaJPRN-UMIN000010258Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine30